Researchers have shown that chimeric antigen receptor T-cell therapy (CAR-T) successfully treats another non-cancerous disease. Eleven patients with refractory autoimmune hemolytic anemia (AIHA) were all brought into remission with this therapy. CAR-T therapy is originally used to treat hematological tumors, but it also shows promising results in refractory systemic autoimmune rheumatic diseases. The therapy targets B-lymphocytes, which play a key role in autoimmune processes. In pilot clinical trials in patients with SLE, systemic scleroderma and antisynthetase syndrome, there was a significant improvement in condition, disappearance of autoantibodies and remission without further immunosuppressive treatment. All patients experienced improvement within 3 months, including reduction of proteinuria and normalization of autoantibodies, with complete clearance of circulating B-cells.[1]